Columbia University scientists have developed a novel RNA-based therapy that shows promise for repairing heart tissue damaged during heart attacks, according to a new study.

The experimental treatment uses a two-step RNA therapy approach designed to help restore cardiovascular function after cardiac events. The therapy works by converting muscle tissue into what researchers describe as a "healing protein factory" that can aid in tissue repair.

The research represents a potential advancement in cardiac treatment, as current therapies for heart attack patients primarily focus on preventing further damage rather than actively repairing tissue that has already been harmed. Heart attacks occur when blood flow to part of the heart muscle is blocked, often resulting in permanent tissue damage.

RNA therapies have gained significant attention in recent years, particularly following the success of mRNA vaccines during the COVID-19 pandemic. These treatments work by delivering genetic instructions to cells, directing them to produce specific proteins that can have therapeutic effects.

The Columbia study adds to growing research into regenerative medicine approaches for cardiac care. However, the therapy would likely require extensive clinical testing before becoming available to patients, following standard protocols for new medical treatments.